Steven H. Bernstein, MD joined The Mark Foundation as its Chief Medical Officer in February 2018. He also serves as the Senior Vice President for Clinical Research and Development at Turnstone Biologics. Previously, Dr. Bernstein served as Chair, Immuno-Oncology Translational
Ryan Schoenfeld is an expert in therapeutics discovery and development, with extensive experience working across functional boundaries in medicinal chemistry, data science, oncology, and related areas of disease biology research. Over the course of 15+ years as a scientific leader
Kasandra Davis joined The Mark Foundation as Office Administrator in June 2017. She brings years of experience in talent acquisition and administrative services.
Rebecca joined The Mark Foundation as Scientific Program Director in November 2017. She came to The Mark Foundation from D. E. Shaw Research, a firm engaged in scientific research and technological development in the field of computational biochemistry.
Patrick Lewis joined The Mark Foundation as Head of Operations and Finance in May 2017. Prior to joining The Mark Foundation, Patrick was at Merck and Co., in diverse roles with increasing responsibility.
Alex Knaster is Chairman and CEO of Pamplona Capital Management, an investment management firm he founded in 2004, with private equity, hedge fund and fund of funds operations. Alex has more than 25 years of experience in the investment banking